Lidds AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
-
-
-
1,028.50
Cost of Goods Sold (COGS) incl. D&A
45.40
24.20
-
-
7,696.70
Gross Income
45.40
24.20
-
-
6,668.20
SG&A Expense
3,940.20
6,991.60
7,848.30
6,634.20
-
EBIT
3,985.60
7,015.80
7,848.30
6,634.20
6,668.20
Non Operating Income/Expense
-
113.10
-
0.40
1.10
Pretax Income
3,890.00
7,063.70
7,815.20
6,634.10
6,669.30
Consolidated Net Income
3,890.00
7,063.70
7,815.20
6,634.10
6,669.30
Net Income
3,890.00
7,063.70
7,815.20
6,634.10
6,669.30
Net Income After Extraordinaries
3,890.00
7,063.70
7,815.20
6,634.10
6,669.30
Net Income Available to Common
3,890.00
7,063.70
7,815.20
6,634.10
6,669.30
EPS (Basic)
-
0.54
0.60
0.38
0.32
Basic Shares Outstanding
-
13,054.40
13,128.50
17,458.10
20,841.50
EPS (Diluted)
-
0.54
0.60
0.38
0.32
Diluted Shares Outstanding
-
13,054.40
13,128.50
17,458.10
20,841.50
EBITDA
3,940.20
6,991.60
7,848.30
6,634.20
6,425.60
Non-Operating Interest Income
95.60
65.20
33.00
0.50
-

About Lidds AB

View Profile
Address
Virdings Allé 32B
Uppsala UP 754 50
Sweden
Employees -
Website http://www.lidds.se
Updated 09/14/2018
LIDDS AB operates as a pharmaceutical company. It engages in the research and development of pharmaceutical products. The company focuses on the development of treatment alternatives and hormonal therapy for prostate cancer.